Thus, we speculate that the significantly higher mutation frequency of BAP1 in the high m5C score group may contribute to the poor prognosis for ccRCC patients and the low mutation frequency of PBRM1 may reduce immunotherapy efficiency for ccRCC patients. The gene discussed is PBRM1; the disease is nonpapillary renal cell carcinoma.